Physician Fee Cuts Also a Possibility

Publication
Article
OncologyONCOLOGY Vol 15 No 10
Volume 15
Issue 10

As if the prospective Medicare cuts in payments for outpatient chemotherapy drugs were not troubling enough, there is another dark Medicare cloud. The American Medical Association (AMA) is predicting that Medicare may also cut physician

As if the prospective Medicare cuts in payments for outpatient chemotherapydrugs were not troubling enough, there is another dark Medicare cloud. TheAmerican Medical Association (AMA) is predicting that Medicare may also cutphysician fees across the board in 2002. A decision on that will not be madeuntil November, when the CMS presents final numbers for the Medicare EconomicIndex (MEI), an inflation adjustment, and the Sustainable Growth Rate (SGR),which describes how much under or over a preset target physicians’ bills toMedicare were in a given year. 

If physicians keep their billing below theincrease in the gross domestic product, then the MEI is increased, leading to ahigher fee "update." In the opposite scenario, the MEI is decreased.Based on preliminary forecasts, the AMA believes that physician fees could becut 2% to 3% in 2002. (That would be after increases of 5.4% and 4.5% in 2000and 2001.) The AMA is trying to get the CMS to make some administrative changesin the way the MEI and SGR are calculated—changes that perhaps would result ina zero change in 2002. But in a letter to medical specialty societies, RobertGilmore, MD, an AMA official, said, "I cannot overemphasize how difficultthis battle could be."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content